Heidelberg Pharma AG presents updated clinical data for lead ATAC candidate pamlectabart tismanitin at the IMS Annual Meeting 2026

Heidelberg Pharma AG (FSE: HPHA) announced new results for its lead antitumor agent pamlectabart tismanitin during the IMS Annual Meeting held in Ladenburg, Germany on 24 September 2026. The press release, issued by the company, reports on data from Phase I and Phase IIa studies in patients with relapsed or refractory multiple myeloma (RRMM).

  • The Phase I data supported a recommended Phase 2 dose of 175 µg/kg for pamlectabart tismanitin.
  • Dose‑escalation studies did not reach the maximum tolerated dose (MTD), indicating a favorable safety profile across the investigated dose range.

Phase IIa dose expansion

  • The Phase IIa expansion is underway in patients with RRMM, following the planned schedule.
  • Early observations confirm that the safety profile remains favorable and that the MTD has not been reached.

Company context

  • Heidelberg Pharma AG is a German biopharmaceutical company specializing in novel cancer therapies and in research on pharmacology, drug metabolism, pharmacokinetics, and molecular biology related to oncology and inflammatory diseases.
  • The company is listed on the Xetra stock exchange; its market capitalization is approximately €118.8 million.
  • As of 24 September 2026, the share price closed at €2.58, with a 52‑week high of €3.34 and a 52‑week low of €2.33.

These developments reinforce Heidelberg Pharma’s position as a clinical‑stage biopharmaceutical company focused on oncology, and the positive safety outcomes may support further advancement of pamlectabart tismanitin in the multiple myeloma treatment landscape.